BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Poised at the Intersection of AI and Precision Medicine

Cardio Diagnostics Holdings (NASDAQ: CDIO) is leveraging artificial intelligence, epigenetics, and genetics to improve the early detection and diagnosis of coronary heart disease through its blood-based Epi+Gen CHD and PrecisionCHD tests, addressing a cardiovascular disease market projected to grow from $393 billion in annual healthcare costs in 2020 to $1.4 trillion by 2050. The company’s proprietary AI-driven Multi-Omics Engine analyzes genetic and epigenetic biomarkers to assess heart attack risk and identify coronary heart disease, including certain nonobstructive forms that conventional diagnostic methods may miss. Cardio Diagnostics has strengthened its commercialization efforts through securing finalized CMS reimbursement rates and dedicated CPT laboratory codes, expanding U.S. provider partnerships as well as launching its first international expansion in India. With a proprietary, AI-driven platform with reimbursement milestones, growing provider adoption and evidence supporting the ability to detect what traditional tools miss, the company occupies a position that is scientifically grounded and commercially actionable in the diagnostics landscape.

To view the full article, visit https://ibn.fm/8eOOt

About Cardio Diagnostics Holdings Inc.

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (“AI”)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN